$84.08
1.22% day before yesterday
Nasdaq, Sep 06, 10:04 pm CET
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Biomarin Pharmaceutical Stock price

$84.08
-2.79 3.21% 1M
-2.69 3.10% 6M
-12.34 12.80% YTD
-6.92 7.60% 1Y
-0.87 1.02% 3Y
+11.95 16.57% 5Y
+14.89 21.52% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-1.04 1.22%
ISIN
US09061G1013
Symbol
BMRN
Sector
Industry

Key metrics

Market capitalization $16.01b
Enterprise Value $15.88b
P/E (TTM) P/E ratio 63.48
EV/FCF (TTM) EV/FCF 68.82
EV/Sales (TTM) EV/Sales 6.13
P/S ratio (TTM) P/S ratio 6.18
P/B ratio (TTM) P/B ratio 3.03
Revenue growth (TTM) Revenue growth 18.10%
Revenue (TTM) Revenue $2.59b
EBIT (operating result TTM) EBIT $259.54m
Free Cash Flow (TTM) Free Cash Flow $230.78m
Cash position $1.22b
EPS (TTM) EPS $1.32
P/E forward 41.84
P/S forward 5.71
EV/Sales forward 5.67
Short interest 3.52%
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Biomarin Pharmaceutical forecast:

21x Buy
75%
7x Hold
25%

Analyst Opinions

28 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
75%
Hold
25%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
2,590 2,590
18% 18%
100%
- Direct Costs 575 575
3% 3%
22%
2,015 2,015
23% 23%
78%
- Selling and Administrative Expenses 863 863
11% 11%
33%
- Research and Development Expense 786 786
16% 16%
30%
366 366
113% 113%
14%
- Depreciation and Amortization 106 106
5% 5%
4%
EBIT (Operating Income) EBIT 260 260
267% 267%
10%
Net Profit 257 257
157% 157%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Neutral
PRNewsWire
3 days ago
NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer-term Total Revenue and Non-GAAP Operating Margi...
Neutral
PRNewsWire
4 days ago
NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York.
Neutral
PRNewsWire
9 days ago
SAN RAFAEL, Calif. , Aug. 29, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024, at 7:45 AM PT / 10:45 AM ET in New York, NY.
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,401
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today